

## Errata

---

FEBS 22705

Erratum to: **Stimulation of angiogenesis through cathepsin B inactivation of the tissue inhibitors of matrix metalloproteinases** (FEBS 22347)

[*FEBS Letters* 455 (1999) 286–290]<sup>1</sup>

Georgios Kostoulas<sup>a</sup>, Angela Lang<sup>a</sup>, Hideaki Nagase<sup>b</sup>, Antonio Baici<sup>a,\*</sup>

<sup>a</sup>University Hospital, Department of Rheumatology, CH-8091 Zurich, Switzerland

<sup>b</sup>Department of Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City, KS 66160, USA

Three errors in concentration units were made during the typesetting of the Materials and Methods section, 2.4. *Degradation of TIMPs by cathepsin B*. In three places the character  $\mu$  was wrongly converted to m, so that the section should have been printed as follows (the corrections have been made in bold):

### 2.4. Degradation of TIMPs by cathepsin B

The mature form of cathepsin B was affinity-purified from human kidney [18] and was free of other enzymes as ascertained by electrophoresis, specificity tests with substrates and inhibitors, and N-terminal sequencing. Cathepsin B (containing the pro-form and the single-chain form) was also prepared from conditioned media of dedifferentiated human articular chondrocytes by gel chromatography [12] followed by ion exchange chromatography on DEAE-Sephacel (Pharmacia). Human recombinant, non-glycosylated TIMP-1 whose Asn-30 and Asn-78 were mutated to Ala was expressed in CHO K1 cells and purified on MacroPrep 50Q anion exchange resin (Bio-Rad), Green A Dyematrix (Amicon) and Sephacryl S-200 (Pharmacia). Recombinant human, glycosylated TIMP-1 was expressed in CHO K1 cells and purified using anti-(human TIMP-1) affinity chromatography [19]. Human TIMP-2 was purified from the medium of uterine cervical fibroblasts [20]. The incubation solutions in 50 mM sodium acetate buffer, 2 mM dithiothreitol, 2 mM EDTA, pH 5.50, contained cathepsin B (5  **$\mu$ g/ml** final concentration) and recombinant wild-type or non-glycosylated TIMP-1 (final concentrations in different experiments 100–160  $\mu$ g/ml), or the same cathepsin B concentration and TIMP-2 (final concentrations in different experiments 25–57  **$\mu$ g/ml**). Incubation was performed at 30°C, reaction was stopped at time intervals by making the solution 2 mM with iodoacetic acid, and the progressive disappearance of the original protein band followed by SDS-PAGE. After 5 h of incubation the original proteins were completely digested giving a mixture of peptides. Control experiments included the addition of the cathepsin B-specific inactivator CA-074 at a final concentration of 1  **$\mu$ M**. MALDI-TOF spectra of TIMP-1 and TIMP-2 peptides were accumulated using a Voyager Elite instrumentation (PerSeptive Biosystems, Framingham, MA, USA) with  $\alpha$ -cyano-4-hydroxy-cinnamic acid (5 mg/ml in 50% acetonitrile and 0.1% trifluoroacetic acid in water) as the matrix. Samples were analyzed in pulsed extraction reflectron mode using an acceleration voltage of 20 kV, a pulse delay time of 75 ns, a grid voltage of 55% and a guide voltage of 0.05%. Peptide sequences matching the determined molecular masses were calculated with the software PAWS (Protein Analysis WorkSheet) of ProteoMetrics (<http://www.proteo-metrics.com>).

---

\*Corresponding author. Center of Experimental Rheumatology, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland. Fax: (41) (1) 635 6805. E-mail: [baici@ruz.unizh.ch](mailto:baici@ruz.unizh.ch)

<sup>1</sup> PII: S0014-5793(99)00897-2

FEBS 22936

Erratum to: **Sphingosylphosphorylcholine induces cytosolic  $\text{Ca}^{2+}$  elevation in endothelial cells in situ and causes endothelium-dependent relaxation through nitric oxide production in bovine coronary artery** (FEBS 22521)

[*FEBS Letters* 457 (1999) 375–380]<sup>1</sup>

Kimiko Mogami<sup>a</sup>, Yoichi Mizukami<sup>a</sup>, Natsuko Todoroki-Ikeda<sup>a</sup>, Masato Ohmura<sup>a,b</sup>, Kazuki Yoshida<sup>a</sup>, Saori Miwa<sup>a</sup>, Masunori Matsuzaki<sup>b</sup>, Masako Matsuda<sup>c</sup>, Sei Kobayashi<sup>a,\*</sup>

<sup>a</sup>First Department of Physiology, School of Medicine, Yamaguchi University, 1-1-1 Minamikogushi, Ube 755-8505, Japan

<sup>b</sup>Second Department of Medicine, School of Medicine, Yamaguchi University, 1-1-1 Minamikogushi, Ube 755-8505, Japan

<sup>c</sup>School of Allied Health Sciences, Yamaguchi University, 1-1-1 Minamikogushi, Ube 755-8505, Japan

The correct affiliations of Sei Kobayashi and Masato Ohmura is given above.

\*Corresponding author. Fax: (81) (836) 22-2348. E-mail: seikoba@po.cc.yamaguchi-u.ac.jp

<sup>1</sup> PII: S0014-5793(99)01076-5

Febs 23082

Erratum to: **Hormone-activated nuclear receptors inhibit the stimulation of the JNK and ERK signalling pathways in endothelial cells** (FEBS 22697)

[*FEBS Letters* 459 (1999) 272–276]<sup>1</sup>

María Victoria González<sup>a</sup>, José Manuel González-Sancho<sup>a</sup>, Carme Caelles<sup>b</sup>, Alberto Muñoz<sup>a,\*</sup>, Benilde Jiménez<sup>a</sup>

<sup>a</sup>Instituto de Investigaciones Biomédicas 'Alberto Sols', Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, Arturo Duperier 4, E-28029 Madrid, Spain

<sup>b</sup>Facultad de Farmacia, Universidad de Barcelona, E-08028 Barcelona, Spain

In the original publication of this paper, the first three figures were printed in the wrong positions. Whilst the legends were correct, Fig. 1 was printed as Fig. 2, Fig. 2 was printed as Fig. 3 and Fig. 3 was printed as Fig. 1. The Publisher apologises for this mistake to author and readers alike.

\*Corresponding author. Fax: (34)-91-5854587. E-mail: amunoz@biomed.iib.uam.es

<sup>1</sup> PII: S0014-5793(99)01257-0